Omacor reduces triglycerides by reducing the concentration of very low density lipoproteins deca durabolin before and after , moreover, it actively influences haemostasis, reducing the synthesis of thromboxane A2, and slightly increasing the clotting time.
Omacor delays triglyceride synthesis in the liver.
Reduction in triglyceride levels helps increase peroxisome p – oxidation of fatty acids (reducing the amount of free fatty acids available to the synthesis of triglycerides).
Raising high-density lipoprotein (HDL) is very small and is not permanent. It is significantly less than after administration of fibrates. The results of observations (over 3.5 years) of patients taking Omacor 1 g of the drug per day, showed a significant reduction in the combined index, including all-cause mortality and non-fatal myocardial infarction and stroke.
During and after the absorption of fatty acids such as omega-3, there are 3 main ways to their metabolism:
- fatty acid (FA) is first delivered to the liver, where included in various categories of lipoproteins and lipids are directed to peripheral stocks;
- phospholipids of cell membrane phospholipids, lipoproteins replaced, after which fatty acids may act as precursors of various eicosanoids;
- Most fatty acids oxidized to provide energy needs.
Secondary prevention of myocardial infarction (in combination with other standard methods of treatment: statins, antiplatelet agents, beta-blockers, ACE inhibitors).
endogenous hypertriglyceridemia – as a supplement to the diet, with its lack of effectiveness:
- type IV (as monotherapy)
- types IIb / III (in deca durabolin before and after combination with statins – when the concentration is high triglycerides).
: Hypersensitivity to the drug. The exogenous hypertriglyceridemia (giperhilomikronemii type 1). Pregnancy and lactation.
Age 18 years (effectiveness and safety have not been established).
Older age (over 70 years).
Severe hepatic dysfunction.
Concomitant use with fibrates.
Simultaneous treatment with oral anticoagulants.
Severe trauma, surgery (due to the risk of increasing the time bleeding).
Dosing and Administration
Inside, along with the food.
For secondary prevention of myocardial infarction it is recommended to take 1 capsule per day. Duration of treatment – on doctor’s advice.
initial dose is two capsules per day. In the absence of therapeutic effect may increase the dose up to 4 capsules per day.
The duration of the treatment – the physician recommendation.
Infectious processes: Infrequent gastroenteritis.
Immune system: Infrequent: Hypersensitivity. Metabolic and Nutritional: hyperglycemia rarely.
From the nervous system: Infrequent: dizziness, dysgeusia (taste perversion); rarely headache.
Vascular disorders: very rare in blood pressure.
On the part of the respiratory system, organs, thoracic and mediastinal disorders: Very rare dryness of the nose.
From the gastrointestinal tract: often indigestion, nausea; infrequent abdominal pain, gastrointestinal disorders, gastritis, pain in the upper abdomen; very rare bleeding from the lower gastrointestinal tract.
Liver: rare liver function abnormalities.
Skin and subcutaneous tissue: rare acne, itchy rash; rarely hives.
Studies: very rarely been an increase in white blood cell count, increased blood lactate dehydrogenase. In patients with hypertriglyceridemia reported a moderate increase in transaminases (ACT, AJIT).
Reports on individual side effects.
Metabolism and nutrition: an increase in insulin requirements (need to increase the standard dose).
Violations of the liver: increased activity of “liver” enzymes.
Disorders of the skin and subcutaneous tissue disorders: acne rosacea, rashes, redness / erythema, urticaria in the chest, neck, and shoulders.
The studies noted anecdotal reports of improvement of creatinine phosphokinase in the blood, myalgia, increased ACT, AJIT, increase in body weight.
Symptoms: may cause side effects or an increase in their severity. Recommended symptomatic therapy.
Interaction with other medicinal products
In an application deca durabolin before and after with oral anticoagulants – the risk of increased bleeding time.
Appointment of Omacor together with warfarin does not lead to any hemorrhagic complications. However, when combined Omakora and warfarin or termination of treatment Omacor is necessary to monitor the prothrombin time. Not recommended simultaneous with fibrates.
In connection with the moderate increase in bleeding time (when taking high doses – 4 capsules) requires monitoring of patients undergoing anticoagulant therapy, and if necessary – correction of the corresponding doses of the anticoagulant. Carrying out this therapy does not preclude the need for conventional control in the treatment of patients.
It is necessary to take into account the increase in bleeding time in patients with an increased risk of haemorrhage (due to severe trauma, surgery, etc.).
Experience study secondary endogenous hypertriglyceridaemia (especially uncontrollable diabetes) is very limited. There is no clinical experience with the treatment of hypertriglyceridemia in combination with fibrates.
When you receive Omacor may moderate increase in activity of “liver” transaminases.
In patients with impaired liver function (especially when taking high doses – 4 capsules) requires regular monitoring of liver function tests (ACT and ALT). Information on the use of the drug Omacor in children, elderly patients older than 70 years or in patients with hepatic impairment available. In patients with deca durabolin before and after impaired renal function dose adjustment is required.